ChAdOx1 nCoV-19 vaccine: asymptomatic efficacy estimates

Lancet. 2021 Jun 12;397(10291):2247-2248. doi: 10.1016/S0140-6736(21)00951-X.

Authors

Elizabeth T Rogawski McQuade¹, James A Platts-Mills²

Affiliations

¹ Department of Public Health Sciences, University of Virginia, Charlottesville, VA 22908, USA; Division of Infectious Diseases and International Health, University of Virginia, Charlottesville, VA 22908, USA. Electronic address: etr5m@virginia.edu.
² Division of Infectious Diseases and International Health, University of Virginia, Charlottesville, VA 22908, USA.

PMID: 34119058
DOI: 10.1016/S0140-6736(21)00951-X

No abstract available

Publication types

Letter
Research Support, N.I.H., Extramural
Comment

MeSH terms

COVID-19 Vaccines
COVID-19*
ChAdOx1 nCoV-19
Humans
SARS-CoV-2
Vaccines*

Substances

COVID-19 Vaccines
Vaccines
ChAdOx1 nCoV-19

Grants and funding

K01 AI130326/AI/NIAID NIH HHS/United States